TPST — Tempest Therapeutics Share News
0.000.00%
Last trade - 00:00U.S. RESEARCH ROUNDUP-Ashland, Oportun Financial, Palomar Holdings
Advisory: Alert incorrectly tagged to Tempest Therapeutics withdrawn
Advisory: Alert incorrectly tagged to Tempest Therapeutics withdrawn
Tempest Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Overstock.com, Biocept, Birkenstock
U.S. STOCKS ON THE MOVE-Moderna, Aldeyra Therapeutics, Colgate-Palmolive
U.S. STOCKS ON THE MOVE-Tempest Therapeutics, Ally Financial, Phio Pharmaceuticals
Tempest Therapeutics jumps on positive data from liver cancer combo therapy trial
U.S. STOCKS ON THE MOVE-Myriad Genetics, Arista Networks, DaVita
Tempest Therapeutics jumps on positive combo therapy liver cancer trial data
Brief: Tempest Adopts Limited Duration Stockholder Rights Plan
Brief: Tempest Releases New Data Demonstrating Superiority Of TPST-1120 Arm Across Multiple Study Endpoints In Randomized First-Line Hcc Study
Brief: Tempest To Report New And Updated Data From Global Randomized Combination Study Of TPST-1120 In First-Line Hepatocellular Carcinoma
Brief: Tempest Therapeutics Inc Says On Sept 6, Co Got Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Brief: Tempest Therapeutics President Tom Dubensky Resigns
Tempest Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Tempest Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Tempest Reports First Quarter 2023 Financial Results And Provides Business Update
Tempest Therapeutics Inc expected to post a loss of 64 cents a share - Earnings Preview